Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, announced the grand ...

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human ...

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...

Superior quality cytokines are crucial for reliable research results and the safe production of cancer cell therapies.

Immutep (IMMP) announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ...

Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...

Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis No change in IMNN-001 favorable safety profile including no reports of serious immune-related adverse ...

At a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a ...

A leukaemia patient told the Daily Express of his six-year cancer-free miracle, thanks to a new drug trial offering fresh ...

We are looking forward to working with the American Red Cross to provide accurate and reproducible allogeneic blood donor characterization for the growing cell therapy sector,” said Rey Mali, Chief ...

The immune system, a complex network comprising cells, tissues, and organs, defends the body against pathogens and diseases. However, disruptions in immune homeostasis, especially the overactivated ...

Lymphocyte counts help doctors diagnose, stage, and treat chronic lymphocytic leukemia (CLL). Other factors, such as the risk level of the type of CLL you have, also play a role. CLL is a slowly ...